Preoperative Chemotherapy for Operable Breast Cancer Is Associated with Better Compliance with Adjuvant Therapy in Matched Stage II and IIIA Patients

Komenaka, Ian K.; Hsu, Chiu Hsieh; Martı́nez, Marı́a Elena; Bouton, Marcia E.; Low, Boo Ghee; Salganick, Jason A.; Nodora, Jesse; Hibbard, Michael L.; Jha, Chandra Bhushan

doi:10.1634/theoncologist.2010-0266

Cited by 17 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The possible mechanism is that the oestrogen level may affect the sensitivity of tumour cells to chemotherapy [14]. Furthermore, it is well known that ER+/PR-tumours have a higher level of growth signalling than ER+/PR + tumours [15,16]. However, in our study, there was no significant difference when analysing the response to NACT among various ER and PR status subgroups (ER+/PR + and ER+/PR-subgroups).…”

Section: Predictive Value Of Pretreatment and Decreased Er And Pr Expcontrasting

confidence: 63%

Assessment of the predictive role of oestrogen and progesterone receptor status in breast cancer patients treated with neoadjuvant chemotherapy: A retrospective analysis for 689 patients

Ye¹,

Chen²,

Fu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : To explore the predictive indicators in hormone receptor (HR)-positive breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) and to evaluate the value of quantitative oestrogen receptor (ER) and progesterone receptor (PR) in predicting tumour response. Methods : Six hundred eighty-nine BC patients with HR-positive status who were treated with anthracycline, epirubicin and taxane NACT treatment were retrospectively analysed. Clinical and pathological features of the patients were used to evaluate the response to NACT. Results : Patients with larger tumour sizes ( OR 1.657 CI 1.186-2.313 p=0.003 ), those who were in a premenopausal status ( OR 1.458 CI 1.039-2.045 p=0.029 ) and those with higher Ki67 levels ( OR 1.735 CI 1.231-2.444 p=0.002 ) exhibited a better therapy response. Among the patients in the postmenopausal subgroup, a lower pretreatment ER or PR expression were associated with a reduction in tumour size, and the cut-off values for ER and PR were 87.5% and 65%, respectively ( p=0.006 and p=0.05 ). Decreased expression of ER and PR was also observed after NACT treatment ( p=0.028 and p<0.001, respectively ) but played only a predictive role in the Her-2-negative subgroup; the cut-off values for decreased ER and PR were 17.5% and 26.5%, respectively ( p=0.044 and p<0.001 ). Conclusions : Semiquantified pretreatment HR expression can be used to predict the response of NACT in postmenopausal BC patients. Decreased ER and PR expression is also associated with a reduction in tumour size in Her-2-negative subtypes treated with NACT.

show abstract

Section: Predictive Value Of Pretreatment and Decreased Er And Pr Expcontrasting

confidence: 63%

Assessment of the predictive role of oestrogen and progesterone receptor status in breast cancer patients treated with neoadjuvant chemotherapy: A retrospective analysis for 689 patients

Ye¹,

Chen²,

Fu³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Another study found that smokers were more likely to be nonadherent. Komenaka and colleagues suggested considering current smoking as a proxy marker for a certain personality type unwilling to adhere to medical guidelines (28). While a low BMI is associated with a high socioeconomic status in the Western world (37,39), its inclusion in the clinical profiles increased the profiles' predictive accuracy.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have identified, with often conflicting results, that factors associated with poor adherence to breast cancer therapy such as type of breast cancer surgery (16,17), severity of side effects (18,19), number of tablets (20)(21)(22), age (11-13, 15, 20, 23, 24), depression and/or the use of antidepressants (24,25), socioeconomic disadvantage (26,27), smoking (28), the impact of breast cancer therapy on quality of life, and the perceived riskbenefit ratio (29).…”

Section: Introductionmentioning

confidence: 99%

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

Markkula

Hietala

Henningson

et al. 2012

Cancer Prevention Research

View full text Add to dashboard Cite

Nonadherence to adjuvant endocrine breast cancer treatment adversely affects disease-free and overall survival. Clinical predictors of nonadherence may allow for specific interventions to reduce nonadherence and improve survival. The aim was to investigate whether clinical characteristics predict nonadherence. Clinical characteristics and information on adherence were obtained from 417 patients with breast cancer in a population-based prospective cohort from southern Sweden using patient charts, pathology reports, and questionnaires filled out at the 1-and 2-year follow-up visits. At the 1-and 2-year follow-up visits, 36 (8.6%) and 33 (9.7%) patients were nonadherent, respectively. Thirteen of the nonadherent patients declined treatment and were never prescribed endocrine treatment. A body mass index (BMI) < 25 kg/m 2 , preoperative current smoking, and drinking alcohol less often than twice a month predicted nonadherence at the 1-year [relative risk (RR), 5.24; 95% confidence interval (CI), 2.75-9.97] and the 2-year visits (RR, 4.07; 95% CI, 2.11-7.84) in patients with at least two of these clinical characteristics. When low histologic grade (I) was added to the model, having at least two of these four clinical characteristics predicted nonadherence at the 1-year (RR, 4.94; 95% CI, 2.46-10.00) and the 2-year visits (RR, 4.74; 95% CI, 2.28-9.87), the two profiles had a sensitivity ranging from 60.6% to 72.7%, whereas the specificity ranged from 68.0% to 78.4%. Nonadherence at the 1-year visit was associated with an increased risk for early breast cancer events (HR, 2.97; 95% CI, 1.08-8.15), adjusted for age and tumor characteristics. In conclusion, two clinical profiles predicted early nonadherence and may allow for targeted interventions to increase adherence if validated in an independent cohort. Cancer Prev Res; 5(5); 735-45. Ó2012 AACR.

show abstract

“…o volume de tecido removido também foi menor no grupo com quimioterapia neoadjuvante (143,6 cm 3 contra 273,9 cm 3 , p=0,003) 8 . esses autores também demonstraram que a aderência ("compliance") ao tratamento foi maior no grupo tratado com quimioterapia neoadjuvante versus adjuvante (100% versus 70%, p=0,0001) 9 .…”

Section: Resultsunclassified

Quimioterapia Neoadjuvante no Câncer de Mama Operável: Revisão da Literatura

Costa

Chagas²

2013

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: A quimioterapia neoadjuvante foi inicialmente utilizada no tratamento sistêmico do câncer de mama localmente avançado e inoperável. Com a base adquirida nessa proposta terapêutica, passou-se a realizar o tratamento neoadjuvante em pacientes com tumores operáveis, e uma ampla experiência se acumula nessa indicação. Objetivos: Realizar uma análise crítica da literatura publicada sobre a quimioterapia neoadjuvante ou primária, priorizando sua indicação no tratamento câncer de mama operável. Método: Os dados da revisão foram identificados através de artigos publicados entre 1997 a 2012, tendo como ferramenta o PubMed/MedLine (www.ncbi.nlm.nih.gov/ pubmed), utilizando as palavras-chave: “neoadjuvant therapy”, “primary systemic therapy”, “breast neoplasms” e “operable breast cancer”. Resultados: Foram encontrados na literatura médica, 1.043 ensaios clínicos e utilizados 25 deles nesta revisão (estudos prospectivos, metanálise e análise de coortes). Conclusão: Após a análise, pode-se concluir que, no câncer de mama operável, a quimioterapia neoadjuvante oferece resultados de sobrevida equivalentes aos obtidos com quimioterapia adjuvante, permitindo aumento do percentual de cirurgias conservadoras, melhora dos desfechos cirúrgicos e adequada avaliação do prognóstico. Os esquemas de tratamento mais estabelecidos empregam antraciclinas, taxanes e, quando indicado, terapia biológica. No campo experimental, seu uso contribui como base para o rápido desenvolvimento de tratamentos melhores e mais eficazes do câncer de mama.

show abstract

Preoperative Chemotherapy for Operable Breast Cancer Is Associated with Better Compliance with Adjuvant Therapy in Matched Stage II and IIIA Patients

Cited by 17 publications

References 29 publications

Assessment of the predictive role of oestrogen and progesterone receptor status in breast cancer patients treated with neoadjuvant chemotherapy: A retrospective analysis for 689 patients

Assessment of the predictive role of oestrogen and progesterone receptor status in breast cancer patients treated with neoadjuvant chemotherapy: A retrospective analysis for 689 patients

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

Quimioterapia Neoadjuvante no Câncer de Mama Operável: Revisão da Literatura

Contact Info

Product

Resources

About